MODEL SPOTLIGHT | B16-F10: A Murine Melanoma Model
While the 5-year survival rates of melanoma patients have been increasing, the rates of melanoma diagnoses have also been increasing. Early promise in recent clinical trials has multiplied the therapeutic approaches being investigated. We have established the murine B16-F10 model to evaluate responses to immuno-oncology agents and to support development of novel therapeutics.
In our B16-F10 model spotlight you can explore the following data about this model:
- Growth kinetics and body weight changes
- Tumor infiltrating immune cell profile
- Response to immune modulatory antibodies
- Response to focal radiation therapy
Find out more about how the B16-F10 model can provide value in your programs.